Thursday, March 16, 2023
UCB and Aitia announced an early drug discovery collaboration focused on the discovery and validation of novel drug targets and drug candidates for Huntingdon’s disease. The collaboration seeks to validate novel drug targets that are causally linked to clinical endpoints in Huntington's disease.
This strategic collaboration will combine the use of novel Huntington’s disease drug targets from Aitia’s Gemini Digital Twins with UCB’s expertise in drug research and preclinical model systems in neurodegeneration with the aim to accelerate the discovery of new therapies for people living with Huntington's disease.
This collaboration will be an investment in next generation science and technology, allowing to accelerate the understanding of human pathobiology and explore the potential of developing novel medicines through AI. Moreover this collaborate gains deeper insights into the underlying mechanisms of this complex disease and hope to drive major advancements in drug discovery and development faster than ever before.